Pomerantz’s Rising Stars Honored by the National Law Journal

Pomerantz is proud to announce that Of Counsel Omar Jafri and associate Daryoush Behbood have been recognized by the National Law Journal as Rising Stars of the Plaintiffs Bar in 2021. In this new category in its Elite Trial Lawyers competition, the National Law Journal honored a select group of lawyers under the age of 40 who “demonstrated repeated success in cutting-edge work on behalf of plaintiffs over the last 18 months [and] possess a solid track record of clients wins over the past three to five years.”

Omar played an integral role in In re Juno Therapeutics, Inc. Securities Litigation, in which the Firm, as Lead Counsel, achieved a $24 million settlement for the Class in 2018. Omar also played an integral role where Pomerantz was Lead or Co-Lead Counsel in In re Aveo Pharmaceuticals, Inc. Securities Litigation ($18 million settlement, which was more than four times larger than the SEC’s fair fund recovery in its parallel litigation); Sudunagunta v. NantKwest, Inc. ($12 million settlement); Cooper v. Thoratec Corporation et. al. ($11.9 million settlement); Thomas v. MagnaChip Semiconductor Corp. Securities Litigation ($6.2 million settlement with majority shareholder, Avenue Capital); Schaeffer v. Nabriva Therapeutics plc et. Al. ($3 million settlement); and In re Sequans Communications S.A. Securities Litigation ($2.75 million settlement). Omar currently plays a key role in the Firm’s representation of investors in connection with several complex cases that involve billions of dollars in damages. Omar has also been recognized by Super Lawyers® as a Rising Star in Securities Litigation.

Daryoush graduated with honors from the University of Texas School of Law in 2015 and, after clerking for the Fourteenth Court of Appeals, hejoined Pomerantz as an associate in 2019 to focus his practice on corporate governance litigation. Daryoush was instrumental in securing a victory in Collins v. Gilead Sciences, Inc. on behalf of Pomerantz’s client, a Gilead stockholder who had demanded to inspect certain of Gilead’s books and records to investigate potential derivative or class action claims. Following a Section 220 trial, the Court ordered Gilead to give plaintiffs access to nearly all the books and records requested and took the unusual step of inviting plaintiffs to file a motion for attorneys’ fees. Daryoush also played an integral role in securing a similar victory in Melvin Gross v. Biogen, Inc., with the Delaware Court of Chancery citing the Court’s opinion in Gilead. Here, Daryoush gained access to books and records for a stockholder who alleged a credible basis to suspect wrongdoing by Biogen following government investigations into alleged violations of Medicare’s anti-kickback rules.